Measuring the effectiveness of adrenaline as a treatment for cardiac arrest

Phase 1

• Conditions: Out of hospital cardiac arrest; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2014-000792-11-GB
• Lead Sponsor: niversity of Warwick

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-05-23
• Study Completion: 2019-07-04
• Last Update Posted: 20 July 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 8014

Inclusion Criteria

1.Cardiac arrest in out of hospital environment
2.Advanced life support initiated and / or continued by ambulance service clinician

Are the trial subjects under 18? yes
Number of subjects for this age range: 160
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 2440
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5400

Exclusion Criteria

1.Known or apparent pregnancy
2.Known or apparently aged under 16 years
3.Cardiac arrest secondary to anaphylaxis
4.Adrenaline given prior to arrival of ambulance service clinician

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To determine the clinical effectiveness of adrenaline in the treatment of out of hospital cardiac arrest, measured as survival to 30 days. ;Secondary Objective: To evaluate the effects of adrenaline on survival and recovery of survivors at 3, 6 and 12 months after the cardiac arrest, and to establish the cost-effectiveness of using adrenaline.;Primary end point(s): Survival to 30 days post cardiac arrest.;Timepoint(s) of evaluation of this end point: 30 days